TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Brief Summary: This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA 200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults.

Approximately 75 to 100 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Intervention Type: DRUG; Name: oritavancin; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tigecycline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ampicillin-sulbactam | Intervention Type: DRUG; Name: Tigecycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ampicillin-sulbactam; Assigned to Arm(s): 2
D: Arm Label: TR-701 FA; Type: EXPERIMENTAL; Interventions: Drug: TR-701 FA | Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: TR-701 FA; Assigned to Arm(s): TR-701 FA | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Contraceptive Effectiveness in Obese Women
Brief Summary: The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.


Options:
A: N/A
B: Arm Label: Immediate implant; Type: EXPERIMENTAL; Interventions: Device: Sino-implant (II) | Arm Label: Delayed implant; Type: ACTIVE_COMPARATOR; Interventions: Device: Sino-implant (II) | Intervention Type: DEVICE; Name: Sino-implant (II); Assigned to Arm(s): Delayed implant, Immediate implant
C: Arm Label: copper intrauterine device; Type: ACTIVE_COMPARATOR; Interventions: Device: copper-releasing intrauterine device, Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: LNG-releasing intrauterine system; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: ENG-releasing implant; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Intervention Type: DEVICE; Name: copper-releasing intrauterine device; Assigned to Arm(s): copper intrauterine device | Intervention Type: DEVICE; Name: ENG-releasing implant; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-releasing intrauterine system; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-IUS; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device
D: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Contraceptive Effectiveness in Obese Women
Brief Summary: The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.


Options:
A: Arm Label: LCS12; Type: EXPERIMENTAL; Interventions: Drug: LCS12 | Arm Label: LCS16; Type: EXPERIMENTAL; Interventions: Drug: LCS16 | Intervention Type: DRUG; Name: LCS12; Assigned to Arm(s): LCS12 | Intervention Type: DRUG; Name: LCS16; Assigned to Arm(s): LCS16
B: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15
C: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane
D: Arm Label: Normal Weight group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Arm Label: Obese group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Intervention Type: DRUG; Name: Low dose formulation; Assigned to Arm(s): Normal Weight group, Obese group | Intervention Type: DRUG; Name: High dose formulation; Assigned to Arm(s): Normal Weight group, Obese group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Brief Summary: This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: docetaxel + S-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1 | Intervention Type: DRUG; Name: docetaxel + S-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: S-1; Assigned to Arm(s): 2
B: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
C: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair
Brief Summary: Does corticosteroid (dexamethasone) have an effect on the postoperative period after laparoscopic hernia repair, when it comes to pain, postoperative nausea and vomiting and convalescence. This randomized, double-blinded study compares dexamethasone versus placebo. The patients are recommended one day of convalescence. The medicine or placebo is given before operation. The patients fill out questionnaire before operation and three hours after operation and in the following three days. The patients also register when they return to normal activities and work.


Options:
A: Arm Label: Aprepitant group; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant group | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo group
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ramosetron with saline | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: ramosetron with dexamethasone | Intervention Type: DRUG; Name: ramosetron with saline; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: ramosetron with dexamethasone; Assigned to Arm(s): Group B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Ondansetron | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: NaCl; Assigned to Arm(s): 6
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair
Brief Summary: Does corticosteroid (dexamethasone) have an effect on the postoperative period after laparoscopic hernia repair, when it comes to pain, postoperative nausea and vomiting and convalescence. This randomized, double-blinded study compares dexamethasone versus placebo. The patients are recommended one day of convalescence. The medicine or placebo is given before operation. The patients fill out questionnaire before operation and three hours after operation and in the following three days. The patients also register when they return to normal activities and work.


Options:
A: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
C: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
D: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair
Brief Summary: Does corticosteroid (dexamethasone) have an effect on the postoperative period after laparoscopic hernia repair, when it comes to pain, postoperative nausea and vomiting and convalescence. This randomized, double-blinded study compares dexamethasone versus placebo. The patients are recommended one day of convalescence. The medicine or placebo is given before operation. The patients fill out questionnaire before operation and three hours after operation and in the following three days. The patients also register when they return to normal activities and work.


Options:
A: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic NaCl | Arm Label: dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone phosphate | Intervention Type: DRUG; Name: dexamethasone phosphate; Assigned to Arm(s): dexamethasone | Intervention Type: DRUG; Name: Isotonic NaCl; Assigned to Arm(s): Placebo
D: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.
Brief Summary: Objective: To investigate whether the complex intervention will improve the appropriateness of prescriptions in elderly multi-morbid patients with multi-medication in general practices.

Study hypothesis: The primary objective of the study is to determine whether the complex intervention will improve the appropriateness of prescriptions compared to usual care. The primary efficacy endpoint is the change in the Medication Appropriateness Index (MAI) score from baseline (T0) to 6 months after baseline (T1), i.e. the difference MAI T1-T0.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Optimization strategy (complex intervention) | Intervention Type: OTHER; Name: Optimization strategy (complex intervention); Assigned to Arm(s): Intervention arm
B: Arm Label: Statin Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Statin Choice Decision Aid, Other: Usual care for antihyperglycemic medication | Arm Label: Diabetes Medication Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Diabetes Medication Choice Decision Aid, Other: Usual care for lipid therapy medication | Intervention Type: OTHER; Name: Diabetes Medication Choice Decision Aid; Assigned to Arm(s): Diabetes Medication Choice Decision Aid | Intervention Type: OTHER; Name: Statin Choice Decision Aid; Assigned to Arm(s): Statin Choice Decision Aid | Intervention Type: OTHER; Name: Usual care for lipid therapy medication; Assigned to Arm(s): Diabetes Medication Choice Decision Aid | Intervention Type: OTHER; Name: Usual care for antihyperglycemic medication; Assigned to Arm(s): Statin Choice Decision Aid
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2
D: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.
Brief Summary: Objective: To investigate whether the complex intervention will improve the appropriateness of prescriptions in elderly multi-morbid patients with multi-medication in general practices.

Study hypothesis: The primary objective of the study is to determine whether the complex intervention will improve the appropriateness of prescriptions compared to usual care. The primary efficacy endpoint is the change in the Medication Appropriateness Index (MAI) score from baseline (T0) to 6 months after baseline (T1), i.e. the difference MAI T1-T0.


Options:
A: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
B: Arm Label: EMR reminder; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder | Arm Label: EMR reminder + Panel management; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder + Panel management | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMR Reminder; Assigned to Arm(s): EMR reminder | Intervention Type: OTHER; Name: EMR Reminder + Panel management; Assigned to Arm(s): EMR reminder + Panel management
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Optimization strategy (complex intervention) | Intervention Type: OTHER; Name: Optimization strategy (complex intervention); Assigned to Arm(s): Intervention arm
D: Arm Label: Standard (static) Computer Alerts; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard (static) Computer Alerts | Arm Label: Enhanced Computer Alerts; Type: EXPERIMENTAL; Interventions: Other: Enhanced Computer Alerts | Intervention Type: OTHER; Name: Standard (static) Computer Alerts; Assigned to Arm(s): Standard (static) Computer Alerts | Intervention Type: OTHER; Name: Enhanced Computer Alerts; Assigned to Arm(s): Enhanced Computer Alerts

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.
Brief Summary: Objective: To investigate whether the complex intervention will improve the appropriateness of prescriptions in elderly multi-morbid patients with multi-medication in general practices.

Study hypothesis: The primary objective of the study is to determine whether the complex intervention will improve the appropriateness of prescriptions compared to usual care. The primary efficacy endpoint is the change in the Medication Appropriateness Index (MAI) score from baseline (T0) to 6 months after baseline (T1), i.e. the difference MAI T1-T0.


Options:
A: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medication review | Arm Label: Observational arm; Type: OTHER; Interventions: Behavioral: Medication review | Intervention Type: BEHAVIORAL; Name: Medication review; Assigned to Arm(s): Intervention group, Observational arm
C: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Optimization strategy (complex intervention) | Intervention Type: OTHER; Name: Optimization strategy (complex intervention); Assigned to Arm(s): Intervention arm

Answer: D